Copyright
©The Author(s) 2016.
World J Gastroenterol. Jan 7, 2016; 22(1): 417-426
Published online Jan 7, 2016. doi: 10.3748/wjg.v22.i1.417
Published online Jan 7, 2016. doi: 10.3748/wjg.v22.i1.417
Table 1 Advantages and disadvantages of nuclear magnetic resonance and mass spectroscopy
| NMR | MS | |
| Sensitivity (detection limit) | Usually micromolar (nanomolar with cryosonde) | Picomolar |
| Reproducibility | High | Low |
| Detected | Non targeted approach | Targeted approach |
| Metabolite | Detect metabolite Only if contain proton on the molecule | Need specific preparation to well detected some metabolites (Lipids…) |
| Metabolite identification | Easy, using 1D and/or 2D spectra and databases | More difficult, need sometime complementary analysis |
| Number of know identifiable metabolites | More than 200 | More than 4000 |
| Sample | Simple preparation (minimal add of D2O, Buffer and sometime reference) | Preparation more complex (protein extraction, etc.) |
| Non destructive method | Destructive method | |
| Need 400 μL (less than 10 μL with microprobe) | Need few microliters | |
| Type of sample | Liquid (urine, whole blood, serum, plasma, etc.) and intact tissue | Liquid |
| Cost of machine | Very high | High |
| Cost of sample analysis | Lower | Higher |
| Signal acquisition time | 5 to 15 min for 1D spectra | Around 10 min |
| More longer for 2D spectra (few hours) |
Table 2 Examples of metabolite changes involved in liver diseases in nuclear magnetic resonance based metabolomics approaches
| Metabolites | Variation | Model/pathology | Sample | Ref. |
| 2OH butyrate | - | HBV vs HEV | Plasma | [36] |
| 3OH butyrate | + | ximelagatran toxicity | Plasma | [37] |
| 3OH butyrate | + | Cirrhosis (HBV/alcohol) vs controls | Serum | [24] |
| Acetate | + | acetaminophen toxicity | Urine | [14] |
| Acetate | + | HCC vs cirrhosis | Serum | [29] |
| Acetate | - | Cirrhosis severity | Serum | [20] |
| Acetoacetate | - | Cirrhosis and encephalopathy | Serum | [26] |
| Acetoacetate | + | Cirrhosis (HBV/alcohol) vs controls | Serum | [24] |
| Acetoacetate | - | HBV vs alcohol cirrhosis | Serum | [24] |
| Acetoacetate | - | HBV vs control | Urine | [36] |
| Acetoacetate | + | AIH vs healthy, PBC, OS and DILI | Plasma | [17] |
| Acetone | - | HEV vs control | Plasma | [36] |
| Acetone | + | Cirrhosis (HBV/alcohol) vs controls | Serum | [24] |
| Acetone | - | Decompensated vs compensated cirrhosis | Serum | [25] |
| acetone | - | HCC vs Cirrhosis vs controls | Urine | [31] |
| Acetone | + | AIH vs healthy, PBC, OS and DILI | Plasma | [17] |
| bile acids | + | Cholangicarcinoma vs other causes | Bile | [38] |
| Bile acids | + | HCC vs adjacent tissue | Liver tissue | [39] |
| Carnitine | - | HBV vs control | Plasma | [36] |
| Citrate | + | AIH vs healthy, PBC, OS and DILI | Plasma | [17] |
| Choline | - | fibrosis vs cirrhosis | liver tissue | [21] |
| Choline | + | HCC vs adjacent tissue | liver tissue | [39] |
| Choline, P-choline | - | Cirrhosis severity | serum | [20] |
| Creatine | + | AIH vs healthy, PBC, OS and DILI | Plasma | [17] |
| Creatine | + | high grade HCC vs low grade HCC | Liver tissue | [39] |
| Dimethylamine | + | AIH vs healthy, PBC, OS and DILI | Plasma | [17] |
| Fatty acids | - | Biliary tract cancer | Bile | [33] |
| Fatty acids | - | Non fonctionnal vs fonctionnal graft after liver transplantation | Blood (extraction) | [34] |
| fatty acids | - | Cirrhosis and encephalopathy | Serum | [26] |
| fatty acids (HDL) | - | Cirrhosis severity | Serum | [20] |
| fatty acids (HDL) | - | HCC vs cirrhosis | Serum | [29] |
| Glutamine | + | AIH vs healthy, PBC, OS and DILI | Plasma | [17] |
| Glycerol | + | HEV vs control | Plasma | [36] |
| Glycerol | + | Cirrhosis and encephalopathy | Serum | [26] |
| GPC | - | mild vs moderate fibrosis vs cirrhosis | Liver tissue | [40] |
| GPC | + | HCC vs adjacent tissue | Liver tissue | [39] |
| GPC/P-choline | - | Cirrhosis (HBV/alcohol) vs controls | Serum | [24] |
| Histidine | + | AIH vs healthy, PBC, OS and DILI | Plasma | [17] |
| Isobutyrate | + | Cirrhosis (HBV/alcohol) vs controls | Serum | [24] |
| Isobutyrate | + | HBV vs alcohol cirrhosis | Serum | [24] |
| LDL | - | Cirrhosis (HBV/alcohol) vs controls | Serum | [24] |
| LDL | - | decompensated vs compensated cirrhosis | Serum | [25] |
| lipids | - | HCC vs adjacent tissue | Liver tissue | [39] |
| lipids | - | high grade HCC vs low grade HCC | Liver tissue | [39] |
| OH-butyrate | - | Cirrhosis severity | Serum | [20] |
| P-choline | + | Fibrosis vs cirrhosis | Liver tissue | [21] |
| P-choline | - | Mild vs moderate fibrosis vs cirrhosis | Liver tissue | [40] |
| P-choline | + | HCC vs adjacent tissue | Liver tissue | [39] |
| P-choline | + | Cirrhosis and encephalopathy | Serum | [26] |
| P-choline/GPC | - | High grade HCC vs low grade HCC | Liver tissue | [39] |
| Pdt-choline | + | Cholangicarcinoma vs non cancer | Bile | [38] |
| Pdt-choline | - | Mild vs moderate fibrosis vs cirrhosis | Liver tissue | [40] |
| P-ethanolamine | + | HCC vs adjacent tissue | Liver tissue | [39] |
| P-ethanolamine | + | High grade HCC vs low grade HCC | Liver tissue | [39] |
| P-ethanolamine | + | Fibrosis vs cirrhosis | Liver tissue | [21] |
| PUFA | - | Mild vs moderate fibrosis vs cirrhosis | Liver tissue | [40] |
| Pyruvate | + | AIH vs healthy, PBC, OS and DILI | Plasma | [17] |
| Saturation index | + | Mild vs moderate fibrosis vs cirrhosis | Liver tissue | [40] |
| Total lipids | +, - | Mild vs moderate fibrosis vs cirrhosis | Liver tissue | [40] |
| Total choline/lipids | - | Mild vs moderate fibrosis vs cirrhosis | Liver tissue | [40] |
| Unsaturated FA | + | Fibrose vs cirrhose | Liver tissue | [21] |
| Unsaturated FA | + | Cirrhosis (HBV/Alcohol) vs controls | Serum | [24] |
| VLDL | - | Cirrhosis (HBV/Alcohol) vs controls | Serum | [24] |
| VLDL | - | Decompensated vs compensated cirrhosis | Serum | [25] |
- Citation: Amathieu R, Triba MN, Goossens C, Bouchemal N, Nahon P, Savarin P, Le Moyec L. Nuclear magnetic resonance based metabolomics and liver diseases: Recent advances and future clinical applications. World J Gastroenterol 2016; 22(1): 417-426
- URL: https://www.wjgnet.com/1007-9327/full/v22/i1/417.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i1.417
